ABT-702(腺苷激酶抑制剂)是一种强效、具有口服活性且选择性的腺苷激酶(AK)抑制剂,其 IC50 值为 1.7 nM,对腺苷激酶的选择性比对其他生物靶点(包括环氧合酶-1和-2)高出 1300 倍以上,通过提高游离腺苷水平来减轻糖尿病视网膜病变中的炎症,在体内表现出镇痛和抗炎作用,可用于糖尿病视网膜病变的相关研究。
产品编号: MS-A60331 纯度: 99.61% CAS No.: 214697-26-4 分子式: C22H19BrN6O 分子量: 463.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

ABT-702(腺苷激酶抑制剂)是一种强效、具有口服活性且选择性的腺苷激酶(AK)抑制剂,其 IC50 值为 1.7 nM,对腺苷激酶的选择性比对其他生物靶点(包括环氧合酶-1和-2)高出 1300 倍以上,通过提高游离腺苷水平来减轻糖尿病视网膜病变中的炎症,在体内表现出镇痛和抗炎作用,可用于糖尿病视网膜病变的相关研究。

生物实验数据

生物活性 ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active and selective adenosine kinase (AK) inhibitor with an IC50 value of 1.7 nM that exhibits more than 1300-fold selectivity for adenosine kinase over other biological targets (including cyclooxygenase-1 and -2), alleviates inflammation in diabetic retinopathy by elevating free adenosine levels, demonstrates analgesic and anti-inflammatory effects in vivo, and can be used for research related to diabetic retinopathy.
IC50 & Target

IC50: 1.7 nM (Adenosine kinase, AK)

体外研究
(In Vitro)

ABT-702 (5-50 μM,30 分钟) 通过 A2AAR 以剂量依赖的方式抑制 amadori 糖化白蛋白 (AGA) 诱导的小胶质细胞中 TNF-α 的释放。

体内研究
(In Vivo)

ABT-702 (0.6-100 µmol/kg,腹腔注射或口服,单次给药) 在大鼠中显示出剂量依赖性的镇痛和抗炎作用。
ABT-702 (1.5 mg/kg,腹腔注射,每周两次,持续 8 周) 通过减轻视网膜炎症、氧化应激和细胞死亡来改善小鼠的糖尿病视网膜病变。
ABT-702 (3 mg/kg,腹腔注射,于 FDG 注射前 10 分钟给药) 可在大鼠小脑、中脑区及延髓诱导显著的局部代谢减退。

Animal Model: Male rats
Dosage: 0.6-100 µmol/kg
Administration: i.p., single dose
Result: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia.
Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema.
Exhibited a non-opioid mechanism of action, as its effects were not reversed by the opioid antagonist naloxone.
Showed less potential for developing antinociceptive tolerance compared to morphine.
Animal Model: Male rats
Dosage: 5-100 µmol/kg
Administration: p.o., single dose
Result: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia.
Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema.
The antinociceptive and anti-inflammatory effects were blocked by selective adenosine receptor antagonists, confirming an adenosine-dependent mechanism.
Exhibited a non-opioid mechanism of action.
Showed less potential for developing antinociceptive tolerance compared to morphine.
Had no significant effects on exploratory locomotor activity at lower analgesic doses.
Reduced locomotor activity but did not impair motor coordination at higher doses.
Had no significant effects on heart rate or mean arterial pressure at doses providing maximal anti-hyperalgesia.
Animal Model: Male C57BL/6J (8 weeks) intraperitoneally injected with Streptozotocin (45 mg/kg, 5 consecutive days) to induce diabetes
Dosage: 1.5 mg/kg
Administration: i.p., twice a week for 8 weeks
Result: Showed no effects on final body weight and blood glucose levels in diabetic mice.
Showed lower signs of inflammation (ICAM-1, TNF-α, and microglial activation marker Iba1) compared to control animals receiving the vehicle.
Suppressed the upregulation of A₂A receptor and reduced ENT1 expression.
Reduced oxidative and nitrosative stress in the retina.
Blocked the diabetic effect on AK in diabetic mice as compared with vehicle-treated diabetic mice.
Blocked cell death (decreased cleaved caspase-3 and TUNEL-positive cells) in diabetic mice but did not affect treated normal controls.
Animal Model: Rats
Dosage: 3 mg/kg
Administration: i.p., 10 minutes pre-FDG
Result: Showed significant regional hypometabolism in the cerebellum, mesencephalic region, and medulla compared to the vehicle-treated rats.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 463.33
分子式 C22H19BrN6O
CAS No. 214697-26-4

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (53.96 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1583 mL10.7914 mL21.5829 mL53.9572 mL
5 mM0.4317 mL2.1583 mL4.3166 mL10.7914 mL
10 mM0.2158 mL1.0791 mL2.1583 mL5.3957 mL
15 mM0.1439 mL0.7194 mL1.4389 mL3.5971 mL
20 mM0.1079 mL0.5396 mL1.0791 mL2.6979 mL
25 mM0.0863 mL0.4317 mL0.8633 mL2.1583 mL
30 mM0.0719 mL0.3597 mL0.7194 mL1.7986 mL
40 mM0.0540 mL0.2698 mL0.5396 mL1.3489 mL
50 mM0.0432 mL0.2158 mL0.4317 mL1.0791 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础